The latest update is out from Teleflex ( (TFX) ).
On February 24, 2025, Teleflex amended its credit agreement to facilitate a $500 million delayed draw term loan for acquiring BIOTRONIK’s Vascular Intervention business, enhancing its product suite in coronary and peripheral interventions. Additionally, the company announced the retirement of CFO Thomas E. Powell and the appointment of John R. Deren as his successor, effective April 2, 2025, alongside strategic plans to separate into two publicly traded entities, aiming to streamline operations and increase management focus.
More about Teleflex
Teleflex Incorporated is a company operating in the medical technology industry, primarily focusing on providing medical devices used in critical care and surgery. The company is known for its diversified portfolio of products, including vascular access, interventional, and surgical devices, with a market focus on enhancing patient outcomes and healthcare efficiency.
YTD Price Performance: -0.79%
Average Trading Volume: 506,307
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.25B
Find detailed analytics on TFX stock on TipRanks’ Stock Analysis page.